Abstract
According to ICH Q6A (Specifications: test procedures and acceptance criteria for new drug substances and new drug procedures: chemical substances, (1999) [5]) Guidance, a specification is defined as a list of tests, references to analytical procedures, and appropriate acceptance criteria, which are numerical limits, ranges, or other criteria for the tests described. They are usually proposed by the manufacturers, and subject to the regulatory approval for use. When the acceptance criteria in product specifications cannot be pre-defined based on prior knowledge, the conventional approach is to use data of clinical batches collected during the clinical development phases. This interval may be revised with the accumulated data collected from released batches after drug approval. Dong et al. (J Biopharm Stat 25:317–327, 2015 [1]) discussed the statistical properties of the commonly used intervals and made some recommendations. However, in reviewing the proposed intervals, it is often difficult for the regulatory scientists to understand the difference between the intervals, when some intervals require only pre-specified target proportion of the distribution, and others require confidence level, in addition. Therefore, we propose to use the same confidence level of 95%, and calibrate each interval to the true coverage, under the tolerance interval setting. It is easy to show that the predictive interval and reference interval has the variable true coverage, and increases with the sample size, while tolerance interval covers the fixed true coverage. Based on our study results, we propose somesome appropriate statistical methods, in setting product specifications, to better ensure the product quality for the regulation purpose.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Dong, X., Tsong, Y., Shen, M., Zhong, J.: Using tolerance intervals for assessment of pharmaceutical quality. J. Biopharm. Stat. 25(2), 317–327 (2015)
European Medicines Agency (EMA): Report on the expert workshop on setting specifications for biotech products, London, 9 September 2011
Faulkenberry, G.D., Daly, J.C.: Sample size for tolerance limits on a normal distribution. Technometrics 12(4), 813–821 (1970)
Geisser G.: Predictive Inference: An Introduction. Chapman and Hall (1993)
ICH Guideline Q6A: Specifications: test procedures and acceptance criteria for new drug substances and new drug procedures: chemical substances (1999)
DiFeo, T.J.: Drug product development: a technical review of chemistry, manufacturing, and controls information for the support of pharmaceutical compound licensing activities. Drug Dev. Ind. Pharm. 29, 939–958 (2003)
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
Y. Tsong—The project is completed as part of the requirement of 2017 OB/ORISE summer intern program.
*Disclaimer: This article reflects the views of the authors and should not be construed to represent FDA’s views or policies.
Rights and permissions
Copyright information
© 2019 This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply
About this paper
Cite this paper
Tsong, Y., Wang, T., Hu, X. (2019). Statistical Considerations in Setting Quality Specification Limits Using Quality Data. In: Liu, R., Tsong, Y. (eds) Pharmaceutical Statistics. MBSW 2016. Springer Proceedings in Mathematics & Statistics, vol 218. Springer, Cham. https://doi.org/10.1007/978-3-319-67386-8_1
Download citation
DOI: https://doi.org/10.1007/978-3-319-67386-8_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-67385-1
Online ISBN: 978-3-319-67386-8
eBook Packages: Mathematics and StatisticsMathematics and Statistics (R0)